Compare iShares MSCI South Korea ETF (EWY) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI South Korea ETF trades at $177.36 (market cap $26.25B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: iShares MSCI South Korea ETF is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and Medpace Holdings Inc for 14 Days on average.
| EWY | MEDP | |
|---|---|---|
Market Cap | $26.25B | $16.82B |
Volume | 19,056,075 | 223,093 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $630.19 |
52-Week Low | $80.72 | $393.42 |
Typical Hold Time | 47 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $177.22, down 3.54% amid broad Asian market pressure from rising oil prices and US Treasury yields. Technical indicators show a bearish trend with support at $174 and resistance at $179, while RSI levels suggest potential oversold conditions. The ETF remains heavily concentrated in Samsung and SK hynix, benefiting from AI-driven memory demand but vulnerable to semiconductor cycle volatility.
Outlook remains cautious as geopolitical tensions and high concentration risk offset strong AI fundamentals. The ETF's 148% YoY gain highlights growth potential, but investors face headwinds from global monetary tightening and oil price shocks. Key catalysts include semiconductor investment developments and US-Korea trade relations.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
